Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

the quarter ended December 31, 2007, were $9.0 million, with $7.6 million attributable to research and development. This compares to operating expenses of $15.0 million and research and development expenses of $4.7 million for the same period last year. The Company reported a net loss for the quarter ended December 31, 2007, of $8.2 million, compared to a net loss of $13.1 million for the same period last year.

Revenue for the full year ended December 31, 2007, was $9.9 million compared to revenue of $9.9 million for the same period in 2006. Operating expenses for the 12-month period were $33.6 million, with $28.0 million attributable to research and development. This compares to operating expenses of $34.7 million and research and development expenses of $22.4 million for the same 12-month period last year. The Company reported a net loss for the year ended December 31, 2007, of $23.4 million compared to a net loss of $25.4 million for the same period last year.

For 2008, management has indicated that it is targeting a net cash burn in the range of $22.0 million to $24.0 million.

TorreyPines' complete fiscal 2007 annual report will be available on TorreyPines' Web site: http://www.torreypinestherapeutics.com. Go to the investor center then click on SEC filings.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two mu
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... CIO Review ( http://www.cioreview.com ) has ... Promising Pharma and Life Science Technology Solution Providers 2015. ... software platform for life sciences companies. , The ... of experts and members of CIO Review’s editorial board ... has been on our radar for some time now ...
(Date:4/17/2015)... April 17, 2015 LC Sciences ... technologies, announced today that it is seeking beta ... innovative multiplex PCR based targeted sequencing technology. The ... analysis, that enables accurate detection of rare variants. ... Omega-Primer™ technologies. The company will collaborate with beta ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Cytokinetics, Incorporated ... report first quarter results on Thursday, April 30, 2015 ... senior management will host a conference call at 4:30 ... and the company’s outlook for the future. , The ... accessed from the homepage and in the Investor Relations ...
(Date:4/16/2015)... According to the 2014 Liberty ... source was ranked first among the leading causes ... lifting, pushing, pulling, holding, carrying, or throwing and ... David Round Company takes statistics like this very ... to develop and design equipment that prevents these ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... BEIJING , Feb. 8 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED ), a ... in March 2010 : , , Investor Conference ... Location, Rodman & Renshaw Annual March 7-9, 2010 ... ...
... , , NEW YORK , ... firm specializing in investor relations and corporate communications for domestic ... and Matthew Haines have joined as Managing Directors. ... corporate experience that will serve our clients well,” said ...
... , , , , ... -- 3SBio Inc. (Nasdaq:, SSRX ) ("3SBio" or "the ... researching, developing, manufacturing and marketing,biopharmaceutical products, today announced a ... and commercialize its,Nephoxil(R) pharmaceutical product for the treatment of ...
Cached Biology Technology:China Medical Technologies to Participate Investor Conferences in March 2010 2MBS Value Partners Hires Two New Senior Staff Members 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
(Date:4/14/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... on the growing mobile commerce market, announces that its ... New York Design Awards under the category  ,Product Design ... Design Awards are part of a global multi-disciplinary awards ... from the marketplace, industry and judging panel. Winners will ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... Research at the University of Liverpool has found that Shakespearean ... bard's plays and poetry. , Shakespeare uses a linguistic technique ... noun to serve as a verb. Researchers found that ... means before it understands the function of the word within ...
... of children is effectively an estimate of the probability ... a new study recently published in Journal of Vision, ... Research in Vision and Ophthalmology (ARVO). , Participants ... half of which portrayed actual siblings. In one ...
... in the world. Half the country is arid or ... are scarce. Yet 1.3 billion people live in China, ... At the same time, China's environmental problems of energy and ... are escalating. , The September issue of Frontiers ...
Cached Biology News:Reading Shakespeare has dramatic effect on human brain 2China's environmental challenges 2
UltraPure DNase/RNase-Free Distilled Water is designed for use in all molecular biology applications. It is 0.1-m membrane-filtered and tested for DNase and RNase activity....
...
The S. cerevisiae Hansen strains are the parental yeast strains from which the deletions were derived....
The DNA DipStick Kit is ideal for estimating nucleic acid concentrations and approximate yields. Works with ss- and ds-DNA, RNA, and oligonucleotides at concentrations as low as 0.1 ng/l....
Biology Products: